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Abstract
Objective Multiple studies have shown clear evidence of
vitamin D’s anti-tumor effects on prostate cancer cells in
laboratory experiments, but the evidence has not been
consistent in humans. We sought to examine the associa-
tion between vitamin D and prostate cancer risk in a cohort
of older men.
Methods We conducted a prospective case-cohort study
nested within the multicenter Osteoporotic Fractures in
Men (MrOS) study. Baseline serum 25-OH vitamin D was
measured in a randomly selected sub-cohort of 1,433 men
C65 years old without a history of prostate cancer and
from all participants with an incident diagnosis of prostate
cancer (n = 297). Cox proportional hazards models were
used to evaluate the associations between quartiles of total
25-OH vitamin D and incident prostate cancer, as well as
Gleason score.
Results In comparison with the lowest quartile of 25-OH
vitamin D, the hazard ratio for the highest quartile of 25-
OH vitamin D was 1.22 (CI 0.50–1.72, p = 0.25), no trend
across quartiles (p = 0.94) or association with Gleason
score was observed. Adjustment for covariates did not alter
the results.
Conclusions In this prospective cohort of older men, we
found no association between serum 25-OH vitamin D
levels and subsequent risk of prostate cancer.
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Introduction
Early epidemiologic studies have driven investigations of
the hypothesis that vitamin D signaling plays a role in the
physiology of cancers [1, 2]. Population studies have
shown a fairly consistent link between low levels of vita-
min D and increased risk of some malignancies, for
example adenocarcinoma of the colon. While data from
animal models and cell lines have shown an effect of
vitamin D on prostate cancer biology [3–8], a direct
association between vitamin D levels and prostate cancer
risk in humans has not been consistently demonstrated
[9–21], necessitating additional high-quality studies.
Our study adds analysis of older men to the growing
body of reports on the relationship between serum vitamin
D status and prostate cancer risk. Our study includes men
65 years old or above, who usually have a greater risk of
prostate cancer compared to younger men. Also, our study
includes a large number of participants from areas of the
United States where vitamin D deficiency is common. With
this population at high risk of both prostate cancer and
vitamin D deficiency, our study aims to clarify this rela-
tionship between serum vitamin D status and prostate
cancer risk. In addition, our study has a fair number of
high-grade prostate cancers, allowing for analysis of the




We present analyses from a case-cohort study nested
within a cohort of 5,995 men aged 65 and older who par-
ticipated in the Osteoporotic Fractures in Men (MrOS)
study [22]; a longitudinal study conducted at multiple
centers in the United States (Birmingham, Alabama; Palo
Alto, California; San Diego, California; Minneapolis,
Minnesota; Portland, Oregon; Pittsburgh, Pennsylvania).
The MrOS study was designed to evaluate risk factors for
fractures in older men, with active follow-up for incident
prostate cancer as a secondary endpoint. The participants
were recruited from March 2000 through April 2002.
Exclusion criteria were (1) inability to walk without
assistance from another person, (2) bilateral hip replace-
ments, (3) inability to provide self-reported data, (4) resi-
dence not near a study site, (5) judged by an investigator to
have a medical condition that would result in imminent
death, (6) or inability to understand and sign informed
consent. Initial enrollment included completion of a self-
administered questionnaire and a clinic visit with blood
draw and anthropometric measurements. Physical activity
was assessed using the Physical Activity Score for the
Elderly (PASE) [23]. Details of the assessment have been
previously described [24].
Data and laboratory measurements
Tri-annual follow-up questionnaires were sent to all par-
ticipants in the study to ascertain incident prostate cancer.
If a patient reported being diagnosed with prostate cancer,
medical records were obtained and centrally adjudicated
for stage and Gleason score of the cancer, treatment, serum
PSA, pathology, and biopsy results. Men without prostate
cancer were censored at death or withdrawal from the
study.
Serum vitamin D was analyzed in a sample of 1,433
men with no history of prostate cancer at baseline. In this
group, 82 cases of prostate cancer arose and the remain-
ing 1,351 men were non-cases. At the end of a mean 5.3-
year follow-up period, all additional 215 incident prostate
cancer cases that had occurred outside of the random
sample were identified and included in the serum vitamin
D analyses. This case-cohort design allows for time-to-
event analysis while making efficient use of resources
[25].
Serum 25-OH vitamin D was measured in blood speci-
mens that were obtained at baseline from both the cases
and the non-cases. Archived serum specimens were stored
at -70C. Following incubation for 15 min with stable
isotope 25-OHD3-d6 and precipitation with acetonitrile,
the supernatant was injected onto Cohesive Turbo Flow
Cyclone extraction columns followed by chromatography
on a Supelco LC-18 column and analysis for 25-OH vita-
min D by tandem mass spectrometry (Mayo Clinic Refer-
ence Laboratories, Dr. Ravinder Singh) [26]. Aliquots of a
single serum pool were included in alternate assay runs.
Using the pooled serum, the interassay coefficient of var-
iation for 25-OH vitamin D was 4.4%, and the intraassay
coefficient of variation was 4.9% [24].
Statistical analysis
Baseline characteristics for men with incident prostate
cancer were compared to those with no prostate cancer
diagnosis. Total 25-OH vitamin D was categorized into
quartiles based on the distribution of 25-OH vitamin D in
the randomly sampled sub-cohort. The decision to cate-
gorize into quartiles was made prior to the analyses, and
quartile cut points coincided with clinical categories of
deficiency (\20 ng/ml in the lowest quartile) and suffi-
ciency ([30 ng/ml in the highest quartile). We also
examined 15 ng/ml as an additional cut point for defi-
ciency, as a dichotomous variable. Cox proportional haz-
ards models were used to evaluate the association between
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total 25-OH vitamin D and incident prostate cancer, with
men in the lowest quartile of serum vitamin D considered
as the reference group. To account for potential differences
by disease severity, we also present analyses stratified by
Gleason score. Consistent with clinical practice, a Gleason
score of less than seven was considered less aggressive
while a Gleason score of greater than or equal to seven was
considered representative of more aggressive disease. In
Cox proportional hazards models, Prentice weights were
used to account for the case-cohort design [27]. Factors that
differed between men with incident prostate cancer and
those without, with a p-value \ 0.10, were considered
as potential confounders (including those in Table 1).
Variables were maintained in the final hazard ratio models
Table 1 Comparison of baseline characteristics (n (%), mean ± SD, or median (IQR)) by incident prostate cancer, the MrOS studya
No prostate cancer
(non-cases) (n = 1,351)
Incident prostate
cancer (n = 297)
Incident prostate cancer
Gleason \7 (n = 141)
Incident prostate cancer
Gleason C7 (n = 151)
Demographics
Age 73.6 ± 5.9 72.5 ± 5.1 71.4 ± 4.3 73.4 ± 5.6
p for t test 0.001 <0.0001 0.65
Race
White, non-hispanic 1,217 (90.1) 269 (90.6) 131 (92.9) 133 (88.1)
African-American 42 (3.1) 13 (4.4) 4 (2.8) 9 (6.0)
Asian 37 (2.7) 7 (2.4) 3 (2.1) 4 (2.7)
Hispanic 38 (2.8) 5 (1.7) 1 (0.7) 4 (2.7)
Other 17 (1.3) 3 (1.0) 2 (1.4) 1 (0.7)
p for v2 0.62 0.64 0.44
Study site
Birmingham 232 (17.2) 32 (10.8) 14 (9.9) 17 (11.3)
Minneapolis 200 (14.8) 69 (23.2) 41 (29.1) 27 (17.9)
Palo Alto 222 (16.4) 56 (18.9) 25 (17.7) 31 (20.5)
Pittsburgh 227 (16.8) 50 (16.8) 21 (14.9) 27 (17.9)
Portland 232 (17.2) 41 (13.8) 15 (10.6) 25 (16.6)
San Diego 238 (17.6) 49 (16.5) 25 (17.7) 24 (15.9)
p for v2 0.002 0.0002 0.37
Family history of prostate cancer
First degree 142 (12.8) 50 (20.0) 32 (25.6) 17 (14.2)
p for v2 0.003 <0.0001 0.67
Lifestyle/diet
Smoking—Never 498 (36.9) 126 (42.4) 62 (44.0) 63 (41.7)
Past 801 (59.3) 163 (54.9) 74 (52.5) 85 (56.3)
Current 52 (3.9) 8 (2.7) 5 (3.6) 3 (2.0)
p for v2 0.16 0.25 0.31
Physical activity score (PASE) 146.8 ± 69.3 157.5 ± 71.3 166.4 ± 77.0 150.8 ± 64.5
p for t test 0.02 0.002 0.47
BMI (kg/m2) 27.4 ± 3.7 27.2 ± 3.6 27.1 ± 3.5 27.4 ± 3.6
p for t test 0.60 0.39 0.94
Medication use
Statins 351 (32.3) 88 (37.6) 39 (35.8) 46 (38.3)
p for v2 0.12 0.46 0.18
NSAIDS 106 (9.8) 19 (8.1) 13 (11.9) 6 (5.0)
p for v2 0.44 0.47 0.10
Vitamin D measures
Total serum vitamin D (ng/ml) 25.1 ± 8.1 25.5 ± 7.5 26.0 ± 7.8 25.1 ± 7.3
p for t test 0.42 0.20 0.95
a Statistical tests are for comparisons of each prostate cancer group to the non-case group
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if they altered the hazard ratio for any of the 25-OH
vitamin D quartiles by[5% in the unstratified models or in
the models stratified by Gleason score. These included age,
site, reported physical activity, first degree relative with a
history of prostate cancer, statin use, and non-steroidal
anti-inflammatory drug use. Season of blood draw has been
a significant confounder in prior studies, given the potential
variation in vitamin D status, but adjusting for differences
in season of blood draw did not significantly alter the
hazard ratios in our analysis. In addition, very few cases
occurred in racial or ethnic minority participants. Adjusting
for race either as a dichotomous white/non-white vari-
able or as a five-category variable did not alter the hazard
ratios.
Results
In comparison with the subjects without prostate cancer
(non-cases in Table 1), cases had a similar smoking history
and race distribution, but were slightly younger and had a
significantly higher percent reporting a first degree relative
with prostate cancer (20% compared to 12.8%). The mean
serum 25-OH vitamin D levels were similar in the cases
and the non-cases (25.5 ± 7.5 and 25.1 ± 8.1 ng/mL,
respectively, p = 0.42). The proportions of men with
vitamin D deficiency (defined as\20 ng/mL) were similar
(24% of cases, 25% of non-cases).
For each increasing quartile of 25-OH vitamin D, there
was no significant association with risk of prostate cancer.
In comparison with the lowest quartile of 25-OH vitamin D
(\20 ng/mL), the hazard ratio for the highest quartile of
25-OH vitamin D ([30 ng/mL) was 1.22 (CI 0.50–1.72,
p = 0.25), and no linear trend across quartiles was
observed (p for trend = 0.94). No increased risk of prostate
cancer was observed, even with very severe deficiency
defined as 25-OH vitamin D level less than 15 ng/mL
(HR 0.61, CI 0.36–1.02) (Table 2).
There was no difference in these findings between less
aggressive (Gleason \7) and more aggressive (Gleason
C7) prostate cancers. The hazard ratios did not change after
adjustment for age, area of residence, physical activity
level, family history of prostate cancer, and other
covariates.
In this prospective case-cohort study of older men, we
found no association between serum 25-OH vitamin D
levels and prostate cancer risk, with or without stratifica-
tion by Gleason score. Further, even men with the very
lowest levels of 25-OH vitamin D (\15 ng/mL) did not
appear to be at elevated risk of prostate cancer.
Table 2 Results of Cox regression models for adjudicated incident prostate cancer: adjusted relative risks (95% CI) related to serum vitamin D,
adjusted for confounders as appropriate
Serum vitamin D
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Range (ng/ml) 3.1–19.9 20.0–24.9 25.0–29.9 30–75.6
Mean (ng/ml) 15.5 22.6 27.3 35.2
N at risk (events) 411 (68) 415 (91) 406 (53) 416 (85)
HR (95% CI) Ref 1.35 (0.96–1.89) 0.73 (0.50–1.07) 1.22 (0.50–1.72)
p for trend = 0.94 p = 0.09 p = 0.11 p = 0.25
Adjusted HR* (95% CI) Ref 1.35 (0.91–2.01) 0.64 (0.41–1.00) 1.20 (0.81–1.78)
p for trend = 0.76 p = 0.13 p = 0.05 p = 0.37
Gleason \7 376 (33) 364 (40) 378 (25) 374 (43)
HR (95% CI) Ref 1.37 (0.83–2.26) 0.79 (0.45–1.38) 1.52 (0.93–2.47)
p for trend = 0.32
Adjusted HR* (95% CI) Ref 1.26 (0.69–2.31) 0.65 (0.33–1.28) 1.43 (0.81–2.52)
p for trend = 0.54
Gleason C7 377 (34) 372 (48) 381 (28) 372 (41)
HR (95% CI) Ref 1.33 (0.83–2.16) 0.74 (0.43–1.27) 1.07 (0.65–1.75)
p for trend = 0.62
Adjusted HR* (95% CI) 1.42 (0.82–2.45) 0.75 (0.41–1.39) 1.11 (0.64–1.91)
p for trend = 0.64
Comparison group for all three outcomes is men without prostate cancer
* adjusted for age, site, PASE score, first degree relative with a history of prostate cancer, statin use, and NSAIDS use
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Discussion
In the early 1990s, studies reported an association between
cancer-mortality and geographic region, with the greatest
mortality in northern regions where there is less UV light
exposure [28]. This observation led to the hypothesis that
vitamin D may play a role in cancer development and
progression. The geographic distribution of mortality was
consistent with an inverse relationship between prostate
cancer risk and UV exposure, and presumably, serum
vitamin D levels [29]. This relationship between low UV
exposure and increased risk of prostate cancer has been
confirmed by several other investigators [30–33].
This association of low UV exposure and increased
cancer risk has also been demonstrated in seasonal studies,
where patients who were diagnosed with cancer in the
summer and fall had increased survival compared to
patients diagnosed in the winter [34–36]. For example,
Robsahm et al. found that being diagnosed with prostate
cancer in the summer conferred a 20–30% reduction in the
risk of death. This was supported by Lagunova et al. who
showed that patients diagnosed with prostate cancer in the
summer and autumn had a better prognosis than those
patients diagnosed in winter or spring with a relative risk of
death of 0.80.
Prior to this study, there have been 12 studies that have
examined the association between vitamin D levels and
prostate cancer risk (Table 3). Four of these studies have
suggested an association between increased prostate cancer
risk and low serum levels of vitamin D [9–12]. Two
demonstrated an inverse association between 1,25-OH2
vitamin D levels and prostate cancer risk [10, 11]. The two
other studies demonstrated a link between low 25-OH
vitamin D levels and increased risk of prostate cancer
[9, 12]. Tuohimaa et al. showed an increased risk of
prostate cancer with extreme 25-OH vitamin D deficiency
(\7.6 ng/mL), and they also showed an increased risk of
prostate cancer in those with the highest 25-OH vitamin D
levels suggesting a U-shaped relationship between vitamin
D status and prostate cancer risk [12]. In a 2007 study by






Corder 1993 [10] African-American and
Caucasian men in CA
181 cases, 181
controls
*50% Decreased risk of prostate cancer in men older than
57yo with higher levels of 1,25-OH2, especially in
those men with low 25-OH levels.
Braun 1995 [14] Caucasians in MD 61 cases, 122
controls
*10% Null (measured both 25-OH and 1,25-OH2 levels)
Gann 1996 [16] US physicians 232 cases, 414
controls
*20% High 1,25-OH2 associated with non-significant
reduction in prostate cancer risk
Nomura 1998 [19] Japanese Americans in HI 136 cases, 136
controls
None Null (measured both 25-OH and 1,25-OH2 levels)
Ahohen, 2000 [9] Finnish men 149 cases, 566
controls
[60% Low levels of 25-OH are associated with increased
risk of earlier and more aggressive prostate cancer
in men less than 52yo
Tuohimaa 2004 [12] Scandinavian men 622 cases, 1,451
controls
*50% Both high and low levels of 25-OH are associated
with an increased risk of prostate cancer
Platz 2004 [18] US health professionals 460 cases, 460
controls
*20% Null (measured both 25-OH and 1,25-OH2 levels)
Jacobs 2004 [17] Eastern US Caucasians 83 cases, 166
controls
20% Null (measured both 25-OH and 1,25-OH2 levels)
Li et al. 2007 [11] US Physicians 492 cases, 644
controls
19% Higher levels of 1,25-OH2 were associated with
decreased risk of aggressive prostate cancer in
older ([65yo) men. Also, low 1,25-OH2 in
combination with low 25-OH was associated with
highest risk of aggressive prostate cancer.
Faupel-Badger et al.
2007 [15]
Finnish men 296 cases, 297
controls
*50% Null (measured 25-OH levels only)
Ahn et al. 2008 [13] Caucasian Americans 749 cases, 781
controls
\15% No association with low levels of 25-OH vitamin D
and risk of prostate cancer, possible increased risk
of aggressive prostate cancer with higher 25-OH
vitamin D levels
Travis et al. 2009
[21]
Europeans 652 cases, 752
controls
*25% Null (measured 25-OH levels only)
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Li et al., there was an increased risk of aggressive prostate
cancer when both 1,25-OH2 vitamin D and 25-OH vitamin
D levels were low, but no increased risk was found in
patients with low 25-OH vitamin D levels, but normal
1,25-OH2 vitamin D levels. This additive risk of low levels
of both forms of vitamin D was also shown by Corder et al.
suggesting that perhaps low 25-OH vitamin D levels may
only be associated with increased prostate cancer risk when
they are low enough to effect 1,25-OH2 vitamin D levels.
However, eight other epidemiologic studies have shown no
significant relationship between measured serum vitamin D
levels and prostate cancer risk [13–19, 21].
Additionally, a recent study examined the role of vita-
min D on mortality in patients with known prostate cancer
[20]. Tretli et al. found that higher levels of 25-OH vitamin
D were associated with a better prognosis with a relative
risk of mortality of 0.33 compared with patients who had
lower levels of 25-OH vitamin D.
In the laboratory, prostate carcinoma cell lines and
human specimens have been shown to express vitamin D
receptors [3, 37–39]. Normal prostate cells express alpha-
1-hydroxylase [40, 41] and this activity can be lost when
cancer develops [40, 42], although the incidence of this
loss in patients has not been fully characterized. Extrarenal
alpha-1-hydroxylase, that is responsible for autocrine and
paracrine, but not endocrine vitamin D activation, is
thought to be constitutively active [43, 44] and not down-
regulated by its downstream product, 1,25-OH2 vitamin D
[45]. If this model for the role of vitamin D in prostate
carcinogenesis is correct, one would expect little effect of
25-OH deficiency unless it is severe enough to reduce
autocrine 1,25-OH2 vitamin D production. We did not
detect a relationship between severe vitamin D deficiency
and prostate cancer risk, but our ability to do so was limited
by the modest number of subjects (both cases and non-
cases) with severe deficiency (n = 148). Unfortunately, we
were unable to measure prostatic tissue vitamin D status,
which would clearly be of interest.
While this study had many strengths including rela-
tively large numbers of cases, a representation of multiple
populations across the US where vitamin D deficiency
is common (Portland, OR, and Minneapolis, MN, for
example), a population of older men who are usually at
the greatest risk of prostate cancer, and a relatively large
number of high-grade prostate cancers, the results were
not consistent with the hypothesis that low serum levels
of 25-OH vitamin D increase the risk for prostate cancer.
1,25-OH2 vitamin D, while of interest, was outside the
scope of this study and only 25-OH vitamin D was
measured. When compared to other similar studies
(Table 3), our study had a large, geographically diverse
population, common to less than half the prior studies
[11, 13, 16, 18]. Also, our study had an acceptable
number of highly aggressive prostate cancers (Gleason
C7) compared to other studies.
In general, the studies that were done in locations with a
high prevalence of vitamin D deficiency have more fre-
quently shown a relationship between low vitamin D levels
and prostate cancer risk. Even though our population came
from at least two sites with a high prevalence of vitamin D
deficiency (Portland, OR, and Minneapolis, MN), there was
still no association with 25-OH vitamin D levels and prostate
cancer risk. Despite this, only 24% of participants in this
analysis had vitamin D deficiency (\20 ng/mL), and only
9% had 25-OH vitamin D levels\15 ng/mL. Similarly, as
illustrated by only the top quartile having normal vitamin D
levels ([30 ng/mL), our subjects were largely clustered in
around and just below the normal range of vitamin D. Thus,
it is possible that our cohort did not include enough patients
with severe vitamin D deficiency to demonstrate an effect. It
is also possible that the study did not have a sufficient
number of high-grade cancers. Some recent data and
hypotheses suggest a link between vitamin D status and
prostate cancer aggressiveness rather than incidence [13,
46]. It is also possible that measurement of vitamin D status
in men age 65 or older, as reported here, occurs too late in
life to detect an effect on an oncogenic process that is
thought to be initiated earlier in life [47].
The compelling biologic links between vitamin D and
prostate cancer cell growth has motivated the search for
such a link in patients. For this reason, it is worthwhile to
contemplate possible explanation of how our analysis may
have missed an effect. Nevertheless, the most obvious
explanation for our findings is that an association between
prostate cancer risk and vitamin D status does not exist.
While we cannot rule out the existence of such an associ-
ation in this study, our findings indicate that the vitamin D
status, measured by 25-OH vitamin D, in men age 65 or
older, does not predict for the subsequent development of
prostate cancer.
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